While this may raise some concerns about using STAT3 inhibitors to decrease MDSC populations in the TME, a study by Hellsten et al. assessing the performance of galiellalactone, a STAT3 inhibitor, revealed a significant decrease in the generation of M-MDSC but no increase in tumor-promoting TAMs (Hellsten et al., 2019). The gene discussed is STAT3; the disease is neoplasm.